Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC...
Saved in:
| Published in | BMC medicine Vol. 17; no. 1; pp. 106 - 13 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
05.06.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC.
Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model.
By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3
, CD27
, CD68
, CD103
, and PD1
. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts.
Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. |
|---|---|
| AbstractList | Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Methods Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. Results By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3.sub.intratumoral (T), CD27.sub.T, CD68.sub.peritumoral (P), CD103.sub.T, and PD1.sub.T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, [gamma]-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Conclusions Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. Keywords: Hepatocellular carcinoma, Survival prediction, Immune signature, Prognosis Abstract Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Methods Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. Results By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Conclusions Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC.BACKGROUNDIntratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC.Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model.METHODSTwenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model.By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts.RESULTSBy using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts.Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage.CONCLUSIONSOur ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3.sub.intratumoral (T), CD27.sub.T, CD68.sub.peritumoral (P), CD103.sub.T, and PD1.sub.T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, [gamma]-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Methods Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. Results By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Conclusions Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3 , CD27 , CD68 , CD103 , and PD1 . Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548-0.597; validation cohort, 0.519-0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. |
| ArticleNumber | 106 |
| Audience | Academic |
| Author | Zhou, Jian Zhou, Yu-Fu Jiang, Xi-Fei Fan, Jia Liu, Wei-Ren Tang, Zheng Lau, Wan Yee Tao, Chen-Yang Qu, Wei-Feng Dai, Zhi Qiu, Shuang-Jian Shi, Ying-Hong Zhou, Pei-Yun Fang, Yuan Peng, Yuan-Fei Jin, Lei Tian, Meng-Xin Wang, Han Ding, Zhen-Bin |
| Author_xml | – sequence: 1 givenname: Meng-Xin surname: Tian fullname: Tian, Meng-Xin – sequence: 2 givenname: Wei-Ren surname: Liu fullname: Liu, Wei-Ren – sequence: 3 givenname: Han surname: Wang fullname: Wang, Han – sequence: 4 givenname: Yu-Fu surname: Zhou fullname: Zhou, Yu-Fu – sequence: 5 givenname: Lei surname: Jin fullname: Jin, Lei – sequence: 6 givenname: Xi-Fei surname: Jiang fullname: Jiang, Xi-Fei – sequence: 7 givenname: Chen-Yang surname: Tao fullname: Tao, Chen-Yang – sequence: 8 givenname: Zheng surname: Tang fullname: Tang, Zheng – sequence: 9 givenname: Pei-Yun surname: Zhou fullname: Zhou, Pei-Yun – sequence: 10 givenname: Yuan surname: Fang fullname: Fang, Yuan – sequence: 11 givenname: Wei-Feng surname: Qu fullname: Qu, Wei-Feng – sequence: 12 givenname: Zhen-Bin surname: Ding fullname: Ding, Zhen-Bin – sequence: 13 givenname: Yuan-Fei surname: Peng fullname: Peng, Yuan-Fei – sequence: 14 givenname: Zhi surname: Dai fullname: Dai, Zhi – sequence: 15 givenname: Shuang-Jian surname: Qiu fullname: Qiu, Shuang-Jian – sequence: 16 givenname: Jian surname: Zhou fullname: Zhou, Jian – sequence: 17 givenname: Wan Yee surname: Lau fullname: Lau, Wan Yee – sequence: 18 givenname: Jia surname: Fan fullname: Fan, Jia – sequence: 19 givenname: Ying-Hong surname: Shi fullname: Shi, Ying-Hong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31164128$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kktv1DAUhSNURB_wA9igSEiITdrYsWNng1RVPCpVYlPWlse5STzy2IPtDJoNv507TAszFSiLWDfnfMk9OefFiQ8eiuI1qS8Jke1VIrQjbVWTriINI1X7rDgjAg-iJvzk4HxanKe0rGvKhWAvitOGkJYRKs-Kn_c2pRkq6wfrctTZ-rF029V6CmabIZXJjl7nOUK5jtBbk3E0x43daFdaX67RAR6HP2yeStDRba-szxBXKNYZypT1COUEKAwGnJudjqXR0VgfVvpl8XzQLsGrh_tF8e3Tx_ubL9Xd18-3N9d3leEdyZUkba2bvpONAWaMMMAFJQvOmOybesH5ogHetJTxoTMUejPUzSC4IUZ0Q0Nkc1Hc7rl90Eu1jnal41YFbdXvQYij0jFb40B1QvKBDgvJacd6RhHYD0xglkyyQVJkfdiz1vMCtzS4ftTuCHr8xNtJjWGjWs462gkEvH8AxPB9hpTVyqZdNtpDmJOiVDLOZStqlL59Il2GOXqMClWMSoJE-lc1alwAf2XA95odVF3zrhZUtJSg6vIfKrx6WFmDzcIGwLHh3YFhAu3ylIKbsw0-HQvfHCbyJ4rHmqFA7AUmhpQiDMrYrHcc_ATrFKnVrtBqX2iFhVa7QqsWneSJ8xH-f88vxzj4Sg |
| CitedBy_id | crossref_primary_10_3389_fonc_2021_740484 crossref_primary_10_3389_fcell_2021_686664 crossref_primary_10_11637_aba_2023_36_3_111 crossref_primary_10_1111_cas_14315 crossref_primary_10_3389_fonc_2021_632934 crossref_primary_10_1016_j_jtauto_2020_100067 crossref_primary_10_1038_s41598_021_94329_8 crossref_primary_10_3389_fonc_2022_968202 crossref_primary_10_1007_s12072_023_10511_2 crossref_primary_10_3389_fimmu_2024_1357333 crossref_primary_10_46308_kmj_2023_00220 crossref_primary_10_1186_s12943_020_01229_y crossref_primary_10_1186_s12935_021_02173_7 crossref_primary_10_15616_BSL_2022_28_4_260 crossref_primary_10_3390_cancers13092137 crossref_primary_10_1016_j_phrs_2022_106583 crossref_primary_10_1016_j_phymed_2023_154799 crossref_primary_10_1186_s12935_021_02130_4 crossref_primary_10_1186_s12967_023_04838_5 crossref_primary_10_1007_s10528_024_10830_5 crossref_primary_10_1155_2021_9305277 crossref_primary_10_1371_journal_pone_0231003 crossref_primary_10_24171_j_phrp_2023_0229 crossref_primary_10_1002_hed_26534 crossref_primary_10_1186_s12935_022_02671_2 crossref_primary_10_3389_fonc_2020_00154 crossref_primary_10_1007_s13402_024_00934_w crossref_primary_10_1097_MD_0000000000040408 crossref_primary_10_2147_JHC_S366107 |
| Cites_doi | 10.1016/j.ejca.2016.04.011 10.1016/j.jhep.2012.12.015 10.1038/ncomms13453 10.1200/JCO.2016.68.2153 10.1158/1078-0432.CCR-16-0732 10.1016/j.canlet.2011.03.029 10.1002/hep.27306 10.1158/1078-0432.CCR-12-3497 10.1038/bjc.2016.47 10.1016/j.cell.2017.05.035 10.1200/JCO.2006.09.4565 10.1002/hep.26054 10.1200/JCO.2014.57.9151 10.1053/j.gastro.2015.11.005 10.1146/annurev-med-051013-052304 10.1097/SLA.0000000000002116 10.1158/1055-9965.EPI-15-0578 10.1016/j.jhep.2017.08.013 10.1038/nm.3909 10.1097/SLA.0b013e31829291e9 10.1084/jem.20151636 10.1016/j.jhep.2017.02.026 10.1053/j.gastro.2017.06.007 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E 10.1080/2162402X.2016.1260213 10.1111/j.1478-3231.2006.01342.x 10.1097/SLA.0000000000000747 10.1002/hep.29360 10.1053/j.gastro.2016.02.040 10.7150/thno.28742 10.1159/000488035 10.1136/gutjnl-2015-310814 10.1016/j.jhep.2010.07.044 10.1038/nmeth.3337 10.1038/ni.3775 10.4161/2162402X.2014.985082 10.1200/JCO.2007.15.6521 10.1245/s10434-011-1864-3 10.1038/ni.2573 10.1038/nature16969 10.1097/01.sla.0000254368.65878.da 10.1200/JCO.2010.30.5425 10.1002/hep.27728 10.1038/nrc3245 10.1080/2162402X.2017.1299301 10.1016/j.jhep.2015.10.029 10.1038/s41590-018-0044-z 10.1158/2326-6066.CIR-15-0110 10.1158/1078-0432.CCR-04-0713 10.1002/ijc.29659 10.1126/science.1129139 10.1002/hep.27026 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12916-019-1341-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_9785f2fb85294d429c2df47174484f82 PMC6549297 A590727621 31164128 10_1186_s12916_019_1341_6 |
| Genre | Validation Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAAA NIH HHS grantid: R01 AA020401 – fundername: ; grantid: 2018SHZDZX05 – fundername: ; grantid: 2015AA020401 – fundername: ; grantid: 81472674; 81502486 – fundername: ; grantid: No. 16JC1404000 – fundername: ; grantid: 13SG04 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c591t-8160a3d983ce4cc7ce5721b5448d30b55b3e536245f9c2edcf03f75c1c79f3183 |
| IEDL.DBID | M48 |
| ISSN | 1741-7015 |
| IngestDate | Wed Aug 27 01:31:14 EDT 2025 Thu Aug 21 14:03:32 EDT 2025 Thu Jul 10 18:43:20 EDT 2025 Sat Jul 26 02:20:28 EDT 2025 Tue Jun 17 21:06:51 EDT 2025 Tue Jun 10 20:42:28 EDT 2025 Thu May 22 20:58:49 EDT 2025 Thu Jan 02 22:59:27 EST 2025 Thu Apr 24 23:10:06 EDT 2025 Tue Jul 01 02:51:23 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Survival prediction Hepatocellular carcinoma Prognosis Immune signature |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c591t-8160a3d983ce4cc7ce5721b5448d30b55b3e536245f9c2edcf03f75c1c79f3183 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12916-019-1341-6 |
| PMID | 31164128 |
| PQID | 2242814922 |
| PQPubID | 42775 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9785f2fb85294d429c2df47174484f82 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6549297 proquest_miscellaneous_2284558670 proquest_journals_2242814922 gale_infotracmisc_A590727621 gale_infotracacademiconefile_A590727621 gale_healthsolutions_A590727621 pubmed_primary_31164128 crossref_citationtrail_10_1186_s12916_019_1341_6 crossref_primary_10_1186_s12916_019_1341_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-06-05 |
| PublicationDateYYYYMMDD | 2019-06-05 |
| PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-05 day: 05 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC medicine |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | SL Zhou (1341_CR28) 2016; 150 FZ Ouyang (1341_CR6) 2016; 7 M Garnelo (1341_CR8) 2017; 66 AJ Gentles (1341_CR15) 2015; 21 J Galon (1341_CR49) 2006; 313 J Li (1341_CR37) 2016; 62 M Bilzer (1341_CR5) 2006; 26 H Li (1341_CR21) 2017; 66 A Gabrielson (1341_CR25) 2016; 4 Y Takata (1341_CR27) 2011; 307 B Raziorrouh (1341_CR10) 2016; 150 S Torrecilla (1341_CR3) 2017; 67 C Ma (1341_CR12) 2016; 531 ZQ Wang (1341_CR50) 2016; 22 Q Gao (1341_CR26) 2012; 19 J Qiu (1341_CR36) 2017; 35 SM Brunner (1341_CR42) 2015; 61 B Mlecnik (1341_CR16) 2011; 29 HH Zhang (1341_CR32) 2010; 36 S Li (1341_CR33) 2017; 6 Y Yi (1341_CR31) 2013; 58 YP Fu (1341_CR46) 2016; 114 RL Camp (1341_CR39) 2004; 10 PJ Johnson (1341_CR2) 2015; 33 A Asai (1341_CR29) 2017; 6 C Zheng (1341_CR9) 2017; 169 Y Mok (1341_CR52) 2016; 138 AP Ganesan (1341_CR51) 2017; 18 J Zhou (1341_CR22) 2018; 7 M Ringelhan (1341_CR4) 2018; 19 Y Jiang (1341_CR34) 2018; 267 Q Gao (1341_CR19) 2007; 25 LJ Ma (1341_CR47) 2018; 8 JY Shi (1341_CR18) 2013; 19 C Raggi (1341_CR45) 2014; 59 M Minagawa (1341_CR53) 2007; 245 F Tacke (1341_CR48) 2017; 66 DG Kugler (1341_CR7) 2016; 213 HA Edmondson (1341_CR41) 1954; 7 T Condamine (1341_CR14) 2015; 66 Po-Hong Liu (1341_CR40) 2016; 64 LR Huang (1341_CR11) 2013; 14 AM Newman (1341_CR35) 2015; 12 K Geissler (1341_CR43) 2015; 4 T Utsunomiya (1341_CR54) 2014; 259 WH Fridman (1341_CR13) 2012; 12 L Wang (1341_CR30) 2015; 61 D Sia (1341_CR20) 2017; 153 XD Zhu (1341_CR23) 2008; 26 J Fu (1341_CR24) 2013; 58 JH Shim (1341_CR38) 2015; 261 YW Li (1341_CR17) 2011; 54 LA Torre (1341_CR1) 2016; 25 1341_CR44 |
| References_xml | – volume: 62 start-page: 86 year: 2016 ident: 1341_CR37 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2016.04.011 – volume: 58 start-page: 977 issue: 5 year: 2013 ident: 1341_CR31 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.12.015 – volume: 7 start-page: 13453 year: 2016 ident: 1341_CR6 publication-title: Nat Commun doi: 10.1038/ncomms13453 – volume: 35 start-page: 734 issue: 7 year: 2017 ident: 1341_CR36 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.68.2153 – volume: 22 start-page: 6290 issue: 24 year: 2016 ident: 1341_CR50 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0732 – ident: 1341_CR44 – volume: 307 start-page: 165 issue: 2 year: 2011 ident: 1341_CR27 publication-title: Cancer Lett doi: 10.1016/j.canlet.2011.03.029 – volume: 61 start-page: 627 issue: 2 year: 2015 ident: 1341_CR30 publication-title: Hepatology doi: 10.1002/hep.27306 – volume: 19 start-page: 5994 issue: 21 year: 2013 ident: 1341_CR18 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3497 – volume: 114 start-page: 767 issue: 7 year: 2016 ident: 1341_CR46 publication-title: Br J Cancer doi: 10.1038/bjc.2016.47 – volume: 169 start-page: 1342 issue: 7 year: 2017 ident: 1341_CR9 publication-title: Cell doi: 10.1016/j.cell.2017.05.035 – volume: 25 start-page: 2586 issue: 18 year: 2007 ident: 1341_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.4565 – volume: 58 start-page: 139 issue: 1 year: 2013 ident: 1341_CR24 publication-title: Hepatology doi: 10.1002/hep.26054 – volume: 36 start-page: 841 issue: 4 year: 2010 ident: 1341_CR32 publication-title: Int J Oncol – volume: 33 start-page: 550 issue: 6 year: 2015 ident: 1341_CR2 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.9151 – volume: 150 start-page: 696 issue: 3 year: 2016 ident: 1341_CR10 publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.11.005 – volume: 66 start-page: 97 year: 2015 ident: 1341_CR14 publication-title: Annu Rev Med doi: 10.1146/annurev-med-051013-052304 – volume: 267 start-page: 504 issue: 3 year: 2018 ident: 1341_CR34 publication-title: Ann Surg doi: 10.1097/SLA.0000000000002116 – volume: 25 start-page: 16 issue: 1 year: 2016 ident: 1341_CR1 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-15-0578 – volume: 67 start-page: 1222 issue: 6 year: 2017 ident: 1341_CR3 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.08.013 – volume: 21 start-page: 938 issue: 8 year: 2015 ident: 1341_CR15 publication-title: Nat Med doi: 10.1038/nm.3909 – volume: 259 start-page: 336 issue: 2 year: 2014 ident: 1341_CR54 publication-title: Ann Surg doi: 10.1097/SLA.0b013e31829291e9 – volume: 213 start-page: 3041 issue: 13 year: 2016 ident: 1341_CR7 publication-title: J Exp Med doi: 10.1084/jem.20151636 – volume: 66 start-page: 1300 issue: 6 year: 2017 ident: 1341_CR48 publication-title: J Hepatol doi: 10.1016/j.jhep.2017.02.026 – volume: 153 start-page: 812 issue: 3 year: 2017 ident: 1341_CR20 publication-title: Gastroenterology doi: 10.1053/j.gastro.2017.06.007 – volume: 7 start-page: 462 issue: 3 year: 1954 ident: 1341_CR41 publication-title: Cancer doi: 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E – volume: 6 start-page: e1260213 issue: 1 year: 2017 ident: 1341_CR33 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1260213 – volume: 26 start-page: 1175 issue: 10 year: 2006 ident: 1341_CR5 publication-title: Liver Int doi: 10.1111/j.1478-3231.2006.01342.x – volume: 261 start-page: 939 issue: 5 year: 2015 ident: 1341_CR38 publication-title: Ann Surg doi: 10.1097/SLA.0000000000000747 – volume: 66 start-page: 1920 issue: 6 year: 2017 ident: 1341_CR21 publication-title: Hepatology doi: 10.1002/hep.29360 – volume: 150 start-page: 1646 issue: 7 year: 2016 ident: 1341_CR28 publication-title: Gastroenterology doi: 10.1053/j.gastro.2016.02.040 – volume: 8 start-page: 5690 issue: 20 year: 2018 ident: 1341_CR47 publication-title: Theranostics doi: 10.7150/thno.28742 – volume: 7 start-page: 235 issue: 3 year: 2018 ident: 1341_CR22 publication-title: Liver Cancer doi: 10.1159/000488035 – volume: 66 start-page: 342 issue: 2 year: 2017 ident: 1341_CR8 publication-title: Gut doi: 10.1136/gutjnl-2015-310814 – volume: 54 start-page: 497 issue: 3 year: 2011 ident: 1341_CR17 publication-title: J Hepatol doi: 10.1016/j.jhep.2010.07.044 – volume: 12 start-page: 453 issue: 5 year: 2015 ident: 1341_CR35 publication-title: Nat Methods doi: 10.1038/nmeth.3337 – volume: 18 start-page: 940 issue: 8 year: 2017 ident: 1341_CR51 publication-title: Nat Immunol doi: 10.1038/ni.3775 – volume: 4 start-page: e985082 issue: 1 year: 2015 ident: 1341_CR43 publication-title: Oncoimmunology doi: 10.4161/2162402X.2014.985082 – volume: 26 start-page: 2707 issue: 16 year: 2008 ident: 1341_CR23 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.6521 – volume: 19 start-page: 455 issue: 2 year: 2012 ident: 1341_CR26 publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-1864-3 – volume: 14 start-page: 574 issue: 6 year: 2013 ident: 1341_CR11 publication-title: Nat Immunol doi: 10.1038/ni.2573 – volume: 531 start-page: 253 issue: 7593 year: 2016 ident: 1341_CR12 publication-title: Nature doi: 10.1038/nature16969 – volume: 245 start-page: 909 issue: 6 year: 2007 ident: 1341_CR53 publication-title: Ann Surg doi: 10.1097/01.sla.0000254368.65878.da – volume: 29 start-page: 610 issue: 6 year: 2011 ident: 1341_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.5425 – volume: 61 start-page: 1957 issue: 6 year: 2015 ident: 1341_CR42 publication-title: Hepatology doi: 10.1002/hep.27728 – volume: 12 start-page: 298 issue: 4 year: 2012 ident: 1341_CR13 publication-title: Nat Rev Cancer doi: 10.1038/nrc3245 – volume: 6 start-page: e1299301 issue: 4 year: 2017 ident: 1341_CR29 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1299301 – volume: 64 start-page: 601 issue: 3 year: 2016 ident: 1341_CR40 publication-title: Journal of Hepatology doi: 10.1016/j.jhep.2015.10.029 – volume: 19 start-page: 222 issue: 3 year: 2018 ident: 1341_CR4 publication-title: Nat Immunol doi: 10.1038/s41590-018-0044-z – volume: 4 start-page: 419 issue: 5 year: 2016 ident: 1341_CR25 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0110 – volume: 10 start-page: 7252 issue: 21 year: 2004 ident: 1341_CR39 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0713 – volume: 138 start-page: 311 issue: 2 year: 2016 ident: 1341_CR52 publication-title: Int J Cancer J Int du Cancer doi: 10.1002/ijc.29659 – volume: 313 start-page: 1960 issue: 5795 year: 2006 ident: 1341_CR49 publication-title: Science doi: 10.1126/science.1129139 – volume: 59 start-page: 2251 issue: 6 year: 2014 ident: 1341_CR45 publication-title: Hepatology doi: 10.1002/hep.27026 |
| SSID | ssj0025774 |
| Score | 2.4091508 |
| Snippet | Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel... Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that... Abstract Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 106 |
| SubjectTerms | Adult Aged B cells Biomarkers, Tumor - analysis Biomarkers, Tumor - metabolism Cancer Carcinoma Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - metabolism Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Cohort Studies Colorectal cancer Cytokines Cytotoxicity Female Gene amplification Genomes Hepatocellular carcinoma Hepatology Homogeneity Humans Immune signature Immunohistochemistry Immunophenotyping - methods Liver cancer Liver Neoplasms - diagnosis Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver Neoplasms - pathology Lymphocytes Lymphocytes - pathology Lymphocytes, Tumor-Infiltrating - metabolism Lymphocytes, Tumor-Infiltrating - pathology Male Medical prognosis Medical research Metastasis Middle Aged Multivariate analysis Neoplasm Staging Novels Patient outcomes Patients Performance assessment Prognosis Regression analysis Regression models Subgroups Surgery Survival Survival Analysis Survival prediction Tissue Array Analysis Training Transcriptome Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLadOX06RVoVAoiPihkeVjWhpCIT0lkJuw9UgWtnbY9R5y6W_vjKxd1hTaS6_WCOR5jzT6xNjHEqwC22rhXbBCdhBEG1onwGMxop3VnaMT3csf6uJafr-Bm72nvqgnbIIHnhhHCLAQytBpKBvp0Hva0gX0qDXWFTLo6H0x5m2LqVRqAWY16Qyz0Op0jVGtoMq5EQRgJtQsCkWw_j9d8l5MmvdL7gWg82fsacoc-dm04ufske8P2ePLdDb-gv26ijwUqDKLZQTD7W_58gGlNdgHTCg5tWpEGE9-v6JZI37aoKdAXeOLnieE1TWnrVnuCfj4lMAkVvFyyeg55pG3nt9h_BoH2u-nBlZu6S2ifvjZvmTX59-uvl6I9LqCsNAUo9CFytvKNbqyXlpbWw9YDXaAfHVV3gF0lQcMbxIC8hx_PuRVqMEWtm4CeYJX7KAfev-Gcel045VrUei1VDK0mNZYrFN8pwjlIGQs33Lb2AQ9Ti9gLE0sQbQyk4AMCsiQgIzK2OfdlPsJd-NvxF9IhDtCgsyOH1CRTFIk8y9Fyth7UgAz3T_dGb45gybHJE-VRcY-RQoyfVy-bdMNBmQCgWjNKI9nlGiydj68VTKTXMbaYC5VaqxXS1zJh90wzaQ2uN4PG6LREkCrOs_Y60kndz9dFVj5YraRsXqmrTOuzEf6xV0EFFcE09fUR_-DjW_Zk5LsjDaq4JgdjKuNP8G8bezeRRP9DYDgQT0 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9QwFA-6gngRv62uGkEQhDBtmqTpSVZxWYT1tAtzC20-ZgfGdpzpHPbi3-57aWZ2i7DX5gWavO_k5fcI-cSlVdI2mnkXLBOtDKwJjWPSQzKindWtwxvd81_q7FL8nMt5OnDbprLKvU2Mhtr1Fs_IZ-BquIZwnvOv6z8Mu0bh7WpqoXGfPEDoMizpquY3CZeE2CbdZBZazbbg2wrMn2uGMGZMTXxRhOz_3zDf8kzTqslbbuj0CXmc4kd6MjL8Kbnnu2fk4Xm6IX9O_l7EnWQgOMtVhMTtFnR1DTzr7TWElRQLNiKYJ11vcNYAn3ZgL0Di6LKjCWd1S_GAlnqEP54hpMQmPjEZPIVocuHpFXixocdTfyxjpRY7EnX97-YFuTz9cfH9jKUeC8zKuhiYLlTelK7WpfXC2sp6CTlhKyFrc2XeStmWXoKTEzLUlsPiQ16GStrCVnVAe_CSHHV9518TKpyuvXINsL4SSoQGghsL2YpvFWIdhIzk-902NgGQYx-MlYmJiFZmZJABBhlkkFEZ-XKYsh7RN-4i_oYsPBAicHb80G8WJumhgaRZBh5aLXktHDhjy10AB13BgkXQPCMfUADM-Ar1oP7mRNY5hHqKFxn5HCnQAMDv2ya9Y4BNQCitCeXxhBIU106H90JmkuHYmhsxz8jHwzDOxGK4zvc7pNFCSq2qPCOvRpk8LLosIP-FmCMj1URaJ7syHemWVxFWXCFYX129ufu33pJHHDUID6LkMTkaNjv_DuKyoX0fle8fC0U53A priority: 102 providerName: ProQuest |
| Title | Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31164128 https://www.proquest.com/docview/2242814922 https://www.proquest.com/docview/2284558670 https://pubmed.ncbi.nlm.nih.gov/PMC6549297 https://doaj.org/article/9785f2fb85294d429c2df47174484f82 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBf9gNKXse956zINBoOBV3_oyw9jNKOlDFJGaSDsRdiylAYyu0scWF72t-9OcUzMur34wToZ63Snu9NJvyPkXcKN4CZXoS2dCVnBXZi7vAy5hWBElUYVJWZ0R1ficsy-Tvhkj2zLW7UMXN4b2mE9qfFi_vHXz_VnUPhPXuGVOF2CzYoxLs5ChCcLxT45BMMkUU9HrEsqgHBK1iY27-12TI7SGMKHGEuz71gpD-b_95K9Y7P65yl3DNTFQ_Kg9Szp2UYUHpE9Wz0mR6M2d_6E_L7xPA5hkLO5B8utpnS-htmszRocTopHOTzMJ71bYK8GXq1gJQFZpLOKtgisS4pbt9QiMPIpgk0s_OWTxlLwM6eW3oJ9a2rMB-ABV2qwVlFV_8ifkvHF-c2Xy7CtvhAansVNqGIR5WmZqdRYZow0lkO0WHCI58o0KjgvUsvB_DHuMpPA4F2UOslNbGTmcKV4Rg6qurIvCGWlyqwocxAKyQRzObg9BuIYWwhEQXABibbc1qaFJscKGXPtQxQl9GauNMyVxrnSIiAfui53G1yO_xEPcQo7QoTU9i_qxVS3GqohnOYucYXiScZKMNMmKR2YbgkDZk4lAXmDAqA391O7hUGf8SwCJ1AkcUDeewoUVvh9k7c3HIAJCLLVozzpUYJKm37zVsj0ViM0-FqJgng2gT952zVjTzwmV9l6hTSKca6EjALyfCOT3aC3oh0Q2ZPWHlf6LdXs1gOOC4Txy-TLf37zFTlOUI9wd4qfkINmsbKvwVlrigHZlxM5IIfD86tv1wO_5THwagnP6-H3P-zSQSk |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviDuBwYwEQkKKmjix4zwgtMGmjq0VQp20N5P40lUqSWlTob7wk_iNnJOkZRHS3vYaH0eJz93H_g4hbxjXgutM-tY47cc5d37mMuNzC8mINFrmBiu6w5EYnMdfLvjFDvmzuQuDxyo3NrE21KbUuEfeB1fDJITzjH2c__SxaxRWVzctNBqxOLXrX5CyLT-cfAb-vmXs-Gj8aeC3XQV8zdOw8mUogiwyqYy0jbVOtOWQBeUc8hQTBTnneWQ5mPWYu1Qza7QLIpdwHeokdagB8N5bZDeOIJXpkd3Do9HXb9sUj0M01dZOQyn6S_CmIWbsqY_Aab7oeL-6ScD_ruCKL-ye07zi-I7vk3ttxEoPGhF7QHZs8ZDcHrY1-Ufk97jmnQ-iOp3VILzFhM7WICWlXkMgS_GISA0fSucLnFXBoxVYKJBxOi1oi-y6pLglTC0CLvcRxGJRX2qpLIX4dWLpJfjNqsQ6Ax6cpRp7IBXlj-wxOb-R9X9CekVZ2GeExkamVpgMhC2JRewyCKc05Ec2F4iu4DwSbFZb6RbyHDtvzFSd-kihGgYpYJBCBinhkffbKfMG7-M64kNk4ZYQobrrB-ViolrNV5Cmc8dcLjlLYwPuXzPjICRI4IdjJ5lH9lEAVHPvdWtw1AFPAwguBQs98q6mQJMDn6-z9uYELAKCd3Uo9zqUYCp0d3gjZKo1VUv1T7E88no7jDPx-F1hyxXSyJhzKZLAI08bmdz-dBRCxg1RjkeSjrR2VqU7UkwvayBzgfCAafL8-s_aJ3cG4-GZOjsZnb4gdxlqE26D8T3SqxYr-xKiwip_1aoiJd9vWvv_Aj9jd5U |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tissue-infiltrating+lymphocytes+signature+predicts+survival+in+patients+with+early%2Fintermediate+stage+hepatocellular+carcinoma&rft.jtitle=BMC+medicine&rft.au=Tian%2C+Meng-Xin&rft.au=Liu%2C+Wei-Ren&rft.au=Wang%2C+Han&rft.au=Zhou%2C+Yu-Fu&rft.date=2019-06-05&rft.eissn=1741-7015&rft.volume=17&rft.issue=1&rft.spage=106&rft_id=info:doi/10.1186%2Fs12916-019-1341-6&rft_id=info%3Apmid%2F31164128&rft.externalDocID=31164128 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |